1-20 of 55
Steven Knapper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

S100A4 Expression Protects AML Cells from V-Atpase Mediated Apoptosis Via the Nuclear Receptor Coactivator, NCOA7

Rehab Nawaf S Alanazi, Sian Rizzo, Amanda Gilkes, Steven Knapper, Richard L Darley, Alex Tonks
Journal: Blood
Blood (2024) 144 (Supplement 1): 6129.
https://doi.org/10.1182/blood-2024-205676
Published: 2024
Journal Articles

A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Christopher S. Hourigan, Georgia Andrew, Richard Dillon, Amanda Gilkes, Nuria M Almuina, Sophie King, Thomas Coats, Nicholas McCarthy, Jennifer Byrne, Simone Green, Ulrik Malthe Overgaard, Leanne Berkahn, Louisa Stone, Rasha W Al-Ali, Reem Bahr, Rob Sellar, Mike Dennis, Priyanka Mehta, Robert K Hills, Sylvie D Freeman, Nigel H. Russell
Journal: Blood
Blood (2024) 144 (Supplement 1): 59.
https://doi.org/10.1182/blood-2024-200027
Published: 2024
Journal Articles

Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial

Ian Thomas, Joanna Canham, Sean Johnson, Nuria Marquez, Sophie King, Jane Leahy, Mike Dennis, Nigel H. Russell, Abin Thomas, Steven Knapper
Journal: Blood
Blood (2024) 144 (Supplement 1): 3805.
https://doi.org/10.1182/blood-2024-198870
Published: 2024
Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

CME Clinical Trials & Observations
Sylvie D. Freeman, Abin Thomas, Ian Thomas, Robert K. Hills, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Rachel Moore, Nuria Marquez Almuina, Sarah Burns, Sophie King, Georgia Andrew, Kathleen M. E. Gallagher, Rob S. Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steven Knapper, Nigel H. Russell
Journal: Blood
Blood (2023) 142 (20): 1697–1707.
https://doi.org/10.1182/blood.2023020630
Published: 2023
Includes: Supplemental data
Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Henry Wood, Christianne Bourlon, Austin Kulasekararaj, Albert Borg, Jiri Pavlu, Patrick Elder, David C Taussig, Scott Veitch, Steven Knapper, Jad Othman, Richard Dillon, James Aries, Emily Mitchell, Faisal Basheer, Steven Leak, Vidhya Murthy, Joe W Cross, Priyanka Mehta, Manish Jain, Anjum Khan, Ho Lam, Sarah Leong, Jenny O'Nions, Charles Craddock, Victoria Potter, Mhairi Copland, Pramila Krishnamurthy
Journal: Blood
Blood (2022) 140 (Supplement 1): 9016–9018.
https://doi.org/10.1182/blood-2022-167097
Published: 2022
Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Clinical Trials & Observations
Richard Dillon, Robert Hills, Sylvie Freeman, Nicola Potter, Jelena Jovanovic, Adam Ivey, Anju Shankar Kanda, Manohursingh Runglall, Nicola Foot, Mikel Valganon, Asim Khwaja, Jamie Cavenagh, Matthew Smith, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Steven Knapper, Harpreet Kaur, David Taussig, Priyanka Mehta, Kavita Raj, Igor Novitzky-Basso, Emmanouil Nikolousis, Robert Danby, Pramila Krishnamurthy, Kate Hill, Damian Finnegan, Samah Alimam, Erin Hurst, Peter Johnson, Anjum Khan, Rahuman Salim, Charles Craddock, Ruth Spearing, Amanda Gilkes, Rosemary Gale, Alan Burnett, Nigel H. Russell, David Grimwade
Journal: Blood
Blood (2020) 135 (9): 680–688.
https://doi.org/10.1182/blood.2019002959
Published: 2020
Includes: Supplemental data
Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1266.
https://doi.org/10.1182/blood-2019-124797
Published: 2019
Journal Articles

PKC-Epsilon Overexpression Is Associated with Poor Outcomes in AML and Promotes Chemoresistance and Hematopoietic Stem Cell Quiescence

Rachael Louise Nicholson, BSc, Steven Knapper, DM, Alex Tonks, PhD, Richard L Darley, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2704.
https://doi.org/10.1182/blood-2019-128184
Published: 2019
Journal Articles

Overexpression or Deficiency of RUNX3 Results in Defective Normal Human Hematopoietic Development Similar to RUNX1-ETO Expression in AML

Ana Catarina Menezes, MSc, BSc, Steven Knapper, DM, Richard L Darley, PhD, Alex Tonks, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2527.
https://doi.org/10.1182/blood-2019-130798
Published: 2019
Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Ing S Tiong, MBChB,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MBBS,PhDFRACP, FRCPA, Catherine Vassili, RN,MN, Vanessa Roma Donati, RN, David Taussig, PhD MRCP, FRCPath, Nicola Potter, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Mikel Valganon, PhD, Nigel H. Russell, MD, Kavita Raj, MD PhD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Andrew Grigg, Steven Knapper, DM, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2648.
https://doi.org/10.1182/blood-2019-123899
Published: 2019
Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1818.
https://doi.org/10.1182/blood-2018-99-110356
Published: 2018
Journal Articles

"Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets

Jamshid S Khorashad, MD PhD, Carme Ripoll Fiol, Eva Yebra-Fernandez, MD, Elisabet Nadal-Melsio, MD, Mahroo Karimpoor, PhD, Simone Claudiani, MD, Alistair Reid, BSc, PhD, Steven Knapper, DM, Kikkeri Naresh, Jane Apperley, MB ChB MD, Clinton C. Mason, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1517.
https://doi.org/10.1182/blood-2018-99-115417
Published: 2018
Journal Articles

A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)

Mark W Drummond, MB ChB, PhD FRCPath, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Samuel Munoz Vicente, MSc, Adam J Mead, MD PhD, Christina Yap, MSci, PhD CStat, Frederick Chen, FRCP, FRCPath, PhD, Srinivasan Narayanan, MBBS, MRCP, FRCPath, Dragana Milojkovic, MBBS, PhD, Leyre Navarro-Nunez, PhD, Steven Knapper, BMBCh, MRCP, MRCPath, DM
Journal: Blood
Blood (2017) 130 (Supplement 1): 1649.
https://doi.org/10.1182/blood.V130.Suppl_1.1649.1649
Published: 2017
Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Clinical Trials & Observations
Claire N. Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn Scherber, Amylou C. Dueck, Nicholas C. P. Cross, Ruben Mesa, Mary Frances McMullin
Journal: Blood
Blood (2017) 130 (17): 1889–1897.
https://doi.org/10.1182/blood-2017-05-785790
Published: 2017
Includes: Supplemental data
Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Clinical Trials & Observations
Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett
Journal: Blood
Blood (2017) 129 (9): 1143–1154.
https://doi.org/10.1182/blood-2016-07-730648
Published: 2017
Includes: Supplemental data
Journal Articles

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Marie Gilmour, PhD, Anna Scholtz, Oliver G. Ottmann, MD, Robert K Hills, DPhil, Steven Knapper, Joanna Zabkiewicz, PhD
Journal: Blood
Blood (2016) 128 (22): 2754.
https://doi.org/10.1182/blood.V128.22.2754.2754
Published: 2016
Journal Articles

Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Claire N. Harrison, DM, FRCP, FRCPath, Adam Mead, MD PhD, Sonia Fox, Anesh Panchal, BSc, MSc, Christina Yap, BSc, MSc, PhD, Aimee E Houlton, BSc, MSc, Samah Aliman, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Marion Wood, FRCP, FRCPath, Frederick Chen, MBBS, PhD FRCPath, Jason Coppell, Nicki Panoskaltsis, MD PhD, Steven Knapper, Sahra Ali, FRCPath, Angela Hamblin, MDPhD, Robyn M. Scherber, MD MPH, Holly Geyer, MD, Allison H Scotch, MD MPH, Amylou Constance Dueck, PhD, Nicholas CP Cross, PhD, Ruben A. Mesa, MD, Mary Frances McMullin, MD
Journal: Blood
Blood (2016) 128 (22): 1929.
https://doi.org/10.1182/blood.V128.22.1929.1929
Published: 2016
Journal Articles

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD, Robert K Hills, DPhil, Sylvie Freeman, PhDFRCPath, Steven Knapper, Lars Kjeldsen, MD PhD, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, MD FRCPath, FRCP, Alan K. Burnett, MD FRCP
Journal: Blood
Blood (2015) 126 (23): 221.
https://doi.org/10.1182/blood.V126.23.221.221
Published: 2015
Journal Articles

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Alessandro M. Vannucchi, Ruben A. Mesa, Francisco Cervantes, Ritam Prasad, Janos Jakucs, Anna Elinder, Christian Recher, MDPhD, Peter A. te Boekhorst, Steven Knapper, Tim Somervaille, James P. Dean, Tanya Granston, Adam Mead, Claire N. Harrison
Journal: Blood
Blood (2015) 126 (23): 58.
https://doi.org/10.1182/blood.V126.23.58.58
Published: 2015
Journal Articles

Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients

Robyn M. Scherber, MD MPH, Steven Knapper, Sonia Fox, Heidi E. Kosiorek, MS, Marzia Shah, Sepehr Abdi-Moradi, Adam J Mead, Amylou C. Dueck, PhD, Samah Ailman, Anthony R Green, PhD FRCP, FRCPath, Marion Wood, FRCP, FRCPath, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Fredrick Chen, Jason Coppell, Mary Frances McMullin, MD FRCPath, FRCP, Holly Geyer, MD, Ruben A. Mesa, Claire N. Harrison
Journal: Blood
Blood (2015) 126 (23): 5179.
https://doi.org/10.1182/blood.V126.23.5179.5179
Published: 2015